A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women

Breast Cancer Research and Treatment

Volumn 106, Issue 3, 2007, Pages 389-397

  Mansel, Robert ^a   Goyal, Amit ^a   Nestour, Elisabeth Le ^b   Masini Etévé, Valérie ^b   O'Connell, Katharine ^c   Mansel, R E ^d   Fentiman, I S ^d   Halaska, M ^d   Kudela, M ^d   Strnad, P ^d   Zivny, J ^d   Simek, R ^d   Sak, P ^d   Wisniewska Sawicka, E ^d   Michalska, M ^d   Sirko, I ^d   Michalski, A ^d   Haratym Maj, A ^d   Harvey, J A ^d   Westhoff, C L ^d   Hilt, D C ^d   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Laboratoires BESINS International   (France)

^c Department of Medicine   (United States)

^d NONE

Author keywords

4 Hydroxytamoxifen; Afimoxifene; Breast pain; Breast tenderness; Cyclical mastalgia; Mastalgia

Indexed keywords

4 HYDROXYTAMOXIFEN; AFIMOXIFENE; HORMONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE BURNING; APPLICATION SITE REACTION; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EXFOLIATIVE DERMATITIS; FEMALE; GEL; HORMONE BLOOD LEVEL; HUMAN; INDUCED HYPOTENSION; MASTALGIA; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PALPATION; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA BLEEDING; VISUAL ANALOG SCALE;

ADULT; BREAST DISEASES; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; GELS; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; PAIN MEASUREMENT; TAMOXIFEN;

EID: 35648988473     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9507-x     Document Type: Article

References (34)

1. Ader DN, Browne MW (1997) Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am J Obstet Gynecol 177(1):126-132
2. Ader DN, South-Paul J, Adera T, Deuster PA. (2001) Cyclical mastalgia: prevalence and associated health and behavioral factors. J Psychosom Obstet Gynaecol 22(2):71-76
3. Goodwin PJ, Miller A, Del Giudice ME, Ritchie K (1997) Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. Am J Obstet Gynecol 176(5):998-1005
4. Woods NF, Most A, Dery GK (1982) Prevalence of perimenstrual symptoms. Am J Public Health 72(11):1257-1264
5. Boyle CA, Berkowitz GS, Kelsey JL (1987) Epidemiology of premenstrual symptoms. Am J Public Health 77(3):349-350
6. Preece PE, Mansel RE, Bolton PM, Hughes LM, Baum M, Gravelle IH (1976) Clinical syndromes of mastalgia. Lancet 2(7987):670-673
7. Ader DN, Shriver CD (1997) Cyclical mastalgia: prevalence and impact in an outpatient breast clinic sample. J Am Coll Surg 185(5):482-486
8. Deschamps M, Band PR, Coldman AJ, Hislop TG, Longley DJ (1996) Clinical determinants of mammographic dysplasia patterns. Cancer Detect Prev 20(6):610-619
9. Khanna AK, Tapodar J, Misra MK (1997) Spectrum of benign breast disorders in a university hospital. J Indian Med Assoc 95(1):5-8
10. Leinster SJ, Whitehouse GH, Walsh PV (1987) Cyclical mastalgia: clinical and mammographic observations in a screened population. Br J Surg 74(3):220-222
11. Khan SA, Apkarian AV (2002) The characteristics of cyclical and non-cyclical mastalgia: a prospective study using a modified McGill Pain Questionnaire. Breast Cancer Res Treat 75(2):147-157
12. Mansel RE, Wisbey JR, Hughes LE (1982) Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet 1(8278):928-930
13. Mansel RE, Dogliotti L (1990) European multicentre trial of bromocriptine in cyclical mastalgia. Lancet 335(8683):190-193
14. Fentiman IS, Caleffi M, Brame K, Chaudary MA, Hayward JL (1986) Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1(8476):287-288
15. Fentiman IS, Caleffi M, Hamed H, Chaudary MA (1988) Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Surg 75(9):845-846
16. Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75(2):305-316
17. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138(3):863-870
18. Malet C, Gompel A, Spritzer P, Bricout N, Yaneva H, Mowszowicz I et al (1988) Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 48(24 Pt 1):7193-7199
19. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44(1):112-119
20. Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J et al (2005) Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4 OHT gel to oral tamoxifen. J Clin Oncol 23(13):2980-2987
21. Colak T, Ipek T, Kanik A, Ogetman Z, Aydin S (2003) Efficacy of topical nonsteroidal anti-inflammatory drugs in mastalgia treatment. J Am Coll Surg 196:525-530
22. Irving AD, Morrison SL (1998) Effectiveness of topical non-steroidal anti-inflammatory drugs in the management of breast pain. J R Coll Surg Edinb 43(3):158-159
23. Price DD, McGrath PA, Rafii A, Buckingham B (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17(1):45-56
24. Messinis IE, Lolis D (1988) Treatment of premenstrual mastalgia with tamoxifen. Acta Obstet Gynecol Scand 67(4):307-309
25. Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D (1997) Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol 11(6):393-397
26. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20(19):4040-4049
27. Hammack JE, Mailliard JA, Loprinzi CL, Rospond RM, O'Fallon JR, Wilwerding MB et al (1996) Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. J Pain Symptom Manage 12(4):234-240
28. Mansel RE, Goyal A, Preece P et al (2004) European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol 191:1942-1949
29. Goyal A, Mansel RE (2005) on behalf of the Efamast Study Group. A Randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J 11:41-47
30. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371-1388
31. Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK et al (2004) Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat 85(1):89-97
32. MacCallum J, Cummings J, Dixon JM, Miller WR (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82(10):1629-1635
33. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97(5 Pt 2):855-866
34. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C et al (2005) Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 192(4):1230-1237